THERAPY DOSSIER · th-4c5e04ab0cf3

Native and gamma-irradiated bradykinin-potentiating fraction isolated from scorpion (Leiurus quinquestriatus) venom

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32860604 ↗2020Reported benefit

Bradykinin-Potentiating Activity of a Gamma-Irradiated Bioactive Fraction Isolated from Scorpion (Leiurus quinquestriatus) Venom in Rats with Doxorubicin-Induced Acute Cardiotoxicity: Favorable Modulation of Oxidative Stress and Inflammatory, Fibrogenic and Apoptotic Pathways.

RatChemical/toxinWistarmaleintraperitoneal1 microgram per gram body weightPretreatment for 3 weeks before doxorubicin; final fraction dose 1 h before dox…

Model: Doxorubicin-induced acute cardiotoxicity (doxorubicin 15 mg/kg intraperitoneally on day 21)

Both fractions attenuated doxorubicin-induced ECG changes, biomarker derangements and histological cardiac injury, with the gamma-irradiated fraction restoring biomarkers to normal levels and outperforming the native fraction.

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…